EUCTR2010-018579-12-ITActive, not recruitingNot Applicable
A phase 3, randomised, double-blind, multicentre, parallel-group, placebo- and active-reference, dose-optimisation efficacy and safety study of extended-release Guanfacine Hydrochloride in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder
Shire Pharmaceutical Development ltd0 sites333 target enrollmentStarted: December 28, 2011Last updated:
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 333
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Inclusion Criteria
- •The subject cannot be randomised before all inclusion criteria (including test results) are confirmed. Subjects meeting all of the criteria below may be included in the study. To be eligible for inclusion, each subject must meet each of the following criteria at Screening (Visit 1) and must continue to fulfil these criteria at Baseline (Visit 2) (if reassessed), unless otherwise noted:
- •1.Male or female, aged 6 17 years at the time of consent/assent at Screening (Visit 1).
- •2.Subject’s parent or legally authorised representative (LAR) must provide signature of informed consent, and there must be documentation of assent (if applicable) by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions in accordance with the International Conference on Harmonisation Good Clinical Practice Guidance E6, and applicable regulations before completing any study-related procedures at Screening (Visit 1).
- •3.Subject meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD, combined sub-type, hyperactive/impulsive sub type or inattentive sub-type, based on a detailed psychiatric evaluation using the Kiddie Schedule for Affective Disorders and Schizophrenia – Present and Lifetime version (K-SADS-PL).
- •4.Subject has a minimum ADHD-RS-IV total score of 32 at Baseline (Visit 2).
- •5.Subject has a minimum CGI-S score of 4 at Baseline (Visit 2).
- •6.Subject is functioning at an age-appropriate level intellectually, as judged by the Investigator.
- •7.Subject and parent/LAR understand, are willing, able, and likely to fully comply with the study procedures and restrictions defined in this protocol.
- •8.Subject is able to swallow intact tablets and capsules.
- •9.Subject who is a female of child-bearing potential (FOCP), defined as ?9 years of age or <9 years of age and is menarchal, must have a negative serum beta Human Chorionic Gonadotropin (hCG) pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2) and agree to comply with any applicable contraceptive requirements of the protocol.
- •10.Subject has a supine and standing BP measurement within the 95th percentile for age, sex and height.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Subjects are excluded from the study if any of the following criteria are met at Screening (Visit 1) or at Baseline (Visit 2) (if reassessed), unless otherwise noted:
- •1.Subject has any current, controlled (requiring a prohibited medication or behavioural modification program) or uncontrolled, co-morbid psychiatric diagnosis [except oppositional defiant disorder (ODD)], including any severe comorbid Axis II disorders or severe Axis I disorders such as post traumatic stress disorder (PTSD), bipolar illness, psychosis, pervasive developmental disorder, obsessive-compulsive disorder (OCD), substance abuse disorder, or other symptomatic manifestations or lifetime history of bipolar illness, psychosis or conduct disorder that, in the opinion of the Investigator, contraindicate treatment with SPD503 or STRATTERA or confound efficacy or safety assessments.
- •2.Subject has any condition or illness including clinically significant abnormal Screening (Visit 1) laboratory values which, in the opinion of the Investigator, represents an inappropriate risk to the subject and/or could confound the interpretation of the study. Mild stable asthma treated without the use of beta-2 agonist is not exclusionary.
- •3.Subject has a known history or presence of structural cardiac abnormalities, cardiovascular or cerebrovascular disease, serious heart rhythm abnormalities, syncope, tachycardia, cardiac conduction problems (eg, clinically significant heart block or QT interval prolongation), exercise related cardiac events including syncope and pre syncope, or clinically significant bradycardia.
- •4.Subject has a known family history of sudden cardiac death, ventricular arrhythmia, or QT prolongation.
- •5.Subjects with orthostatic hypotension or a known history of hypertension.
- •6.Subject has glaucoma.
- •7.Subject has clinically significant ECG findings as judged by the Investigator with consideration of the central ECG laboratory’s interpretation.
- •8.Subject has a history of a seizure disorder (other than a single childhood febrile seizure occurring before the age of 3 years) or the presence of a serious tic disorder including Tourette’s Syndrome.
- •9.Current use of any prohibited medication or other medications, including monoamine oxidase inhibitors, herbal supplements, that affect BP or heart rate, potent CYP2D6 inhibitors, medicines known to prolong the QT/QTc interval, medications that lower seizure threshold, pressor agents, beta-2 agonists, medications that affect noradrenaline, medications that have CNS effects or affect cognitive performance, such as sedating antihistamines and decongestant sympathomimetics (inhaled bronchodilators are permitted) or a history of chronic use of sedating medications [ie, antihistamines]) in violation of the protocol specified washout criteria at Baseline (Visit 2).
- •10.Subject has a history of alcohol or other substance abuse or dependence, as defined by DSM-IV-TR (with the exception of nicotine) within the last 6 months.
- •11.Subject has taken another investigational product within 30 days prior to Baseline (Visit 2).
- •12.Subject is significantly overweight based on Center for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts at the Screening (Visit 1). Significantly overweight is defined as a BMI >95th percentile.
- •13.Children aged 6 12 years with a body weight of less than 25.0kg or adolescents aged 13 17 years with a body weight of less than 34.0kg or greater than 91.0kg at Sc
Investigators
Similar Trials
Active, not recruiting
Phase 1
A clinical study to assess how safe and efficient is SPL7013 Gel (VivaGel®) in prevention of repeated episodes of bacterial vaginosis, compared to placebo.recurrent bacterial vaginosisMedDRA version: 17.0Level: PTClassification code 10004055Term: Bacterial vaginosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-000694-39-GBStarpharma Pty Ltd620
Active, not recruiting
Phase 1
A clinical study to assess how safe and efficient is SPL7013 Gel (VivaGel®) in prevention of repeated episodes of bacterial vaginosis, compared to placebo.EUCTR2014-000694-39-HUStarpharma Pty Ltd620
Active, not recruiting
Phase 1
A clinical study to assess how safe and efficient is SPL7013 Gel (VivaGel®) in prevention of repeated episodes of bacterial vaginosis, compared to placebo.recurrent bacterial vaginosisMedDRA version: 18.1Level: PTClassification code 10004055Term: Bacterial vaginosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-000694-39-BGStarpharma Pty Ltd620
Active, not recruiting
Phase 1
A clinical study to assess how safe and efficient is SPL7013 Gel (VivaGel®) in prevention of repeated episodes of bacterial vaginosis, compared to placebo.recurrent bacterial vaginosisMedDRA version: 19.0Level: PTClassification code 10004055Term: Bacterial vaginosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-000694-39-CZStarpharma Pty Ltd620
Completed
Phase 3
Winter-only treatment with omalizumab to prevent asthma exacerbations in childreAsthmaRespiratory - AsthmaACTRN12611001106921niversity of Queensland96